Site-of-Care Strategy: How Employers Can Reduce J-Code and Q-Code Drug Costs

Hospital outpatient departments operate under a different reimbursement structure than independent providers. They charge a facility fee on top of the drug cost — a fee that reflects the hospital's overhead, not the complexity of the infusion. For a straightforward infusion that takes two hours and requires no specialized monitoring, the facility fee adds cost without adding clinical value.

Commercial insurance contracts with hospital systems typically reimburse outpatient infusions at a percentage of the hospital's charges, which are set by the hospital's chargemaster. Those charges bear little relationship to the actual cost of providing the service. The result is that employers pay a significant premium for the hospital setting even when a lower-cost setting would deliver the same clinical outcome.

Independent infusion centers, physician office infusion suites, and home infusion providers operate under different cost structures and typically accept lower reimbursement rates. For clinically appropriate patients, the care is equivalent. The cost is not.

Not every infused medication is a candidate for site-of-care redirection. The clinical appropriateness of a lower-cost setting depends on the medication, the patient's condition, and the monitoring requirements of the infusion.

Medications that are generally good candidates include established biologics for autoimmune conditions — adalimumab, infliximab, vedolizumab, natalizumab, and others — where the patient has completed their initial infusions without adverse reactions and is on a stable maintenance regimen. These patients typically do not require the monitoring infrastructure of a hospital outpatient department.

Medications that are generally not candidates include first infusions of high-risk biologics, medications with complex monitoring requirements, patients with comorbidities that require immediate access to emergency services, and certain oncology infusions where the clinical complexity warrants a higher-acuity setting.

A clinical review process — typically conducted by a specialty pharmacy or infusion management vendor — should evaluate each patient individually rather than applying a blanket policy.

The most effective site-of-care programs combine plan design incentives with clinical outreach and member support.

On the plan design side, employers can structure cost-sharing to make lower-cost settings more attractive — waiving the member's cost-sharing entirely for infusions at preferred sites, while applying standard cost-sharing at hospital outpatient departments. This creates a financial incentive for members to choose the lower-cost setting without mandating it.

Clinical outreach involves proactively identifying members on infused medications and contacting them — through the TPA, PBM, or a specialty infusion vendor — to discuss the option of transitioning to a preferred site. This outreach should be handled by clinically trained staff who can address questions about safety and continuity of care.

Member support is critical. Employees who are comfortable with their current infusion setting may be reluctant to change, particularly if they have a relationship with the clinical staff at their current provider. The transition process should be smooth, well-communicated, and supported by a vendor who can help coordinate the logistics.

The financial impact of a well-executed site-of-care program depends on the plan's current utilization patterns and the specific medications involved, but the savings can be substantial.

For a plan with five members receiving infused biologics at hospital outpatient departments, redirecting even two or three of those members to an independent infusion center or home infusion can generate $50,000 to $150,000 in annual savings, depending on the medications and the differential between settings.

Employers should model the potential savings using their own claims data before implementing a program. The analysis should compare the current site-of-care mix against the expected mix after redirection, using realistic assumptions about member uptake and the cost differential between settings.

Site-of-care strategy is one of the highest-return, lowest-disruption cost-containment tools available to self-funded employers. It does not require changing the drug, changing the physician, or compromising the member's care. It simply asks whether the same care could be delivered in a more cost-effective setting.